Q-omics provides the consensus-scored RN7SL786P profile across patient tissues and cancer cell-line models. RN7SL786P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, RN7SL786P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, RN7SL786P RNA expression shows 8,632 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight READ, PRAD, and LSCC as cancer lineages where RN7SL786P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL786P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL786P survival associations across molecular data types. RN7SL786P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL786P RNA expression–survival associations across cancer types. High RN7SL786P expression shows unfavorable associations in READ, COAD, ACC and UCEC, but favorable associations in KIRC and LIHC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for RN7SL786P RNA expression.
This table summarizes RN7SL786P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL786P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL786P shows higher tumor expression in PRAD. The PRAD box plot shows higher RN7SL786P RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .020).
This table shows molecular features associated with RN7SL786P in patient tissues and cancer cell lines. In patient samples, RN7SL786P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
